Chai Discovery raises $400M for AI drug design at $3.8B valuation

Key Takeaways

1. Chai Discovery raised $400 million on July 14, valuing the company at $3.8 billion.
2. The startup has struck agreements with Pfizer, Novartis, and Eli Lilly for its antibody-design software.
3. UCSF Fresno’s Clinical Research Center oversees more than 60 active clinical trials.
4. Chai says the $400 million Series C will expand its generative models for new medicines.

What changed on July 14

Four hundred million dollars. That is what San Francisco-based Chai Discovery announced it raised on July 14, a Series C round that puts the two‑year‑old company at a $3.8 billion valuation, according to its release and trade filings. The company says it is building a computer-aided design suite for molecules, with a focus on de novo antibody design.

For Central Valley readers, the money matters where new drug candidates meet patients. UCSF Fresno’s Clinical Research Center, which runs more than 60 industry and government trials across two Fresno‑Clovis sites, is the kind of place that sees those candidates when they are ready for people. That is where the national funding headline touches the Valley.

Who is backing the startup

Chai said the round was led by Index Ventures with participation from Kleiner Perkins, Sequoia Capital, and others, and it pegs the valuation at $3.8 billion. Prior rounds drew OpenAI and Thrive Capital. The company’s own timeline lists the New York Times DealBook item that first flagged the raise to a broad audience, along with the Business Wire notice. Numbers line up across those posts.

Where the software shows up

Chai’s model family is already in large‑pharma workflows. Pfizer signed a license in June to use the company’s Chai‑3 system and custom software. Chai also announced collaborations with Novartis and programs with Eli Lilly, including access through Lilly’s TuneLab. None of that guarantees faster approvals, but it moves decisions about which antibodies to try earlier in the process to algorithms that propose designs.

Why the Valley should care

Clinical research capacity here is not abstract. UCSF Fresno runs inpatient trials at Community Regional Medical Center in downtown Fresno and maintains a second site at the Community Cancer Institute in Clovis. If AI‑guided discovery shortens the preclinical slog, more first‑in‑human or early‑phase programs could look beyond the Bay Area and Los Angeles for participants, and that can mean care options closer to home. It could also mean internships or jobs for Fresno State biotech grads and UC Merced students who want to work on data and lab coordination rather than move west. Worth watching, if you run trials in Fresno.

A warm can of Diet Coke sat on the copy desk while I read through the filings and the Fresno trial lists, no one touched it.

Central Valley AI is produced by the CVAI Newsdesk team and developed by Kaweah Tech, a regional firm that builds, deploys, and integrates AI solutions for businesses across California's Central Valley.

Source

https://www.nytimes.com/2026/07/14/business/dealbook/chai-discovery-ai-drug-development.html